Interleukin 10 (I1:10) decreases production of 11:1, II:6, and tumor necrosis factor c~ (TNF-ot) in vitro, and neutralization of II:10 in mice leads to elevation of the same monokines. We test here whether this monokine-suppressing property of I1:10 confers on it the capacity to protect mice from lipopolysaccharide-induced shock, a monokine-mediated inflammatory reaction. A single injection of 0.5-1/~g of recombinant murine IL-10 reproducibly protected BALB/c mice from a lethal intraperitoneal injection of endotoxin. This result was obtained whether the I1:10 was administered concurrently with, or 30 min after the injection of endotoxin. The protective effect of IL-10 was reversed by prior injection of neutralizing anti-I1:10 antibodies, and correlated with a substantial decrease in endotoxin-induced TNF-ot release. These data implicate IL-10 as a candidate for treatment of bacterial sepsis, and more generally as an effective antiinflammatory reagent.
S
evere bacterial infections can result in profound physiological changes including hypotension, fever, tissue necrosis, widespread organ dysfunction, and ultimately death. In the case of gram-negative bacteria, this toxicity is due to endotoxin, a LPS component of the bacterial cell wall (1, 2). Indeed, injection of appropriate doses of LPS into rabbits, mice, and other animals produces changes that are typical of the septic shock syndrome, thus yielding a simple animal model of this inflammatory reaction. Endotoxin-induced toxicity appears to be due to the release of TNF-ot and/or I1:1 from endotoxin-stimulated macrophages/monocytes, since animals can be protected from bacterial and endotoxin-induced shock by neutralization of these monokines, using either mAhs or a physiological I1:1 antagonist termed IL-lra (3, 4) .
IL-10 is a 35-kD protein produced as a result of immune activation by subpopulations of helper T cells (5, 6) , B cells (7, 8) , and macrophage/monocytes (9, 10) . Its numerous in vitro properties (for reviews see references 11 and 12) include suppression of IFN-y production by helper T cells and NK cells (5, 13) , growth costimulation of thymocytes, mast cells, and B cells (14) (15) (16) (17) , and suppression of monokine production (9, 10, 18, 19) . With respect to the latter property, IL-10 profoundly suppresses the induced production of TNF-c~, I1: lot, I1:1B, IL-6, IL-8, and GM-CSF by human monocytes (9) and mouse peritoneal macrophages (10) . In contrast, 11:10 has no effect on constitutive expression of TGF-~/by monocytes (9) and actually upregulates monocyte production of the IL-lra (20) . These in vitro data are supported by in vivo experiments showing that neutralization of I1:10 using specific mAbs leads to elevated levels of circulating TNF-ot and I1:6 in mice (11) . We test here whether the ability of I1:10 to suppress production of TNF-o~ and I1:1 together with its ability to increase Iblra, renders this cytokine capable of protecting mice against endotoxin-induced shock.
Materials and Methods
Mice. 8-wk-old BALB/c female mice were obtained from Simonsen Laboratories (Gilroy, CA). Animals were kept in the DNAX Animal Facility for a consistent 2.5 d before experimentation to help minimize animal-to-animal variation.
Reagents. LPS from Escherichia coli serotype 0111:B4 was purchased from Sigma Immunochemicals (St. Louis, MO). Two separate preparations (designated batch No. 1 and batch No. 2) prepared in an identical manner were used throughout the entire study. Recombinant murine Ibl0 was expressed in E. coli and purified to homogeneity and high sp act ('~1.75 x 106 U/mg) after refolding using hydrophobic and ion exchange chromatography. The protein concentration in the purified preparations was determined by the extinction coef~cient of the protein (1 mg/ml = 0.36 A2s0). This material contained <0.10 etl/mg protein of endotoxin, and remained stable at 4~ for at least 6 too. The specific activity of murine IL-10 was evaluated in the cytokine synthesis inhibition assay (5). Recombinant IL-10 was diluted in PBS containing 0.1% BSA, and administered to mice at various concentrations in a total volume of 100/A. Neutralizing antibody experiments utilized the 2A5 rat IgG1 anti-mouse IL-10 mAb (21), or an isotype control antibody designated GLl13.
Endotoxin-induced Shock. Mice were injected intraperitoneally with 100/zl vol containing doses of endotoxin ranging from 250 to 425/~g. The dose-response curves of animal survival versus endotoxin dose using either of two different preparations of endotoxin are shown in Table 1 . From these data, the LD90 selected for LPS batch No. 1 and LPS batch No. 2 was 350/~g/mouse and 400/zg/mouse, respectively.
TNF-cr Assay. Serum levels of TNF-ot were evaluated using a cytokine-specific ELISA, commercially available from Endogen, Inc. (Boston, MA).
Results and Discussion
To evaluate the effect of Ibl0 on lethal endotoxemia in mice, groups of 20 BALB/c mice were injected intraperitoneaUy with 100 ~1 containing an LDg0 of LPS (between 350 and 400/~g, depending on the batch ofendotoxin), together with an additional 100 #1 containing either PBS or varying amounts of recombinant murine IL-10. In seven independent experiments of this type, mice were completely protected from death resulting from LPS-induced shock when either 0.5, 1.0, or 10 #g of IL-10 was administered to the animal concurrently with the LPS (Fig. i and Table 1 ). In most of these experiments, a substantial proportion of mice were protected after receiving 0.1 or 0.05 #g of Ibl0 at the time of LPS administration ( Fig. 1 and Table 1 ). IL-10-mediated protection of mice from lethal endotoxemia could be blocked by prior adminis- tration of neutralizing anti-I1-10 antibodies, but not by an isotype control antibody (Fig. 2) , confirming the specificity of this effect. A kinetics study revealed that I1-10-mediated protection of mice from lethal endotoxemia was achieved even if the I1-10 was administered 30 min after the LPS injection (Fig. 3) . However, further delays in II.-10 administration substantially reduced protection, and no protection was observed when I1.10 was administered 5 h after the LPS injection (Fig. 3) . Lethal endotoxemia is an undesirable monokine-mediated inflammatory reaction (3, 4) . Since I1-10 has been shown to suppress monokine production by activated macrophages and monocytes in vitro (9, 10, 18, 19) , we considered the possibility that the above I1.10-mediated protection reflected a suppression of monokine production in the endotoxin-induced response. Indeed, sera collected 1, 2, 3, and 4 h after LPS + I1.10 injection indicated a substantial reduction in circulating TNF-cr levels in animals receiving LPS plus I1.10 compared with animals receiving LPS alone (Fig. 4) . Since anti-TNF antibodies similarly protect mice from lethal endotoxemia (3), it is likely that I1.10-induced suppression of TNF-cr at least contributes to the protection this cytokine provides against lethal endotoxemia. Other properties ofi1.10 may also contribute to this protection. In particular, in vitro studies have indicated that I1.10 also suppresses I1.1 production, and upregulates I1.1ra production, by activated macrophages (9, 10, 21) . Both of these consequences will presumably also contribute to protection of mice from lethal endotoxemia in light of previously published reports showing the protective effects of direct I1.1ra administration in this type of model (4) .
In summary, our data indicate that I1.10 is highly effective at protecting mice from lethal endotoxemia, a finding which suggests that I1-10 may be an important candidate for treatment of bacterial sepsis. Whereas numerous other reagents e.g., antibodies to TNF-o~ (3) or endotoxin (22) (23) (24) (25) , as well as the I1.1ra (4) , are currently in clinical trials for treatment of bacterial sepsis, most of these need to be given before endotoxemia induction in animal model experiments in order to obtain optimal protection. One exception to this, the I1. lra, is effective when administered at the time of endotoxemia induction in animal model experiments, but must be administered in quantities large enough to block all endogenous I1.1 receptors (4). Since pharmacological doses of I1.10 produce an array of effects on macrophage/monocyte function that potentially will all contribute to protection from lethal endotoxemia, it will be interesting to compare the efficacy of this cytokine versus other current candidates in the treatment of bacterial sepsis. 
